Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

Publication | Closed Access

DOI

Citations

References

2019

Year

Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, Stefano Cordio, Sara Lonardi, Laura Toppo, Alberto Zaniboni, Roberto Bordonaro, Maria Di Bartolomeo, Gianluca Tomasello,

Clinical Colorectal Cancer

OncologyAcquired ResistanceMedicineColorectal CancerPathologyPhase Ii StudyEgfr/met Dual InhibitionCancer TreatmentPharmacologyRadiation Oncology